BUX

Onfido Achieves ETSI TS 119 461 Certification for High Assurance, Interoperability and Security in Identity Verification

Retrieved on: 
Tuesday, June 6, 2023

Onfido , the global leader in automated identity verification, today announced it has achieved ETSI TS 119 461 certification, the latest European technical standards for identity proofing and trust services by the European Telecommunications Standards Institute (ETSI).

Key Points: 
  • Onfido , the global leader in automated identity verification, today announced it has achieved ETSI TS 119 461 certification, the latest European technical standards for identity proofing and trust services by the European Telecommunications Standards Institute (ETSI).
  • The independent certification establishes Onfido as the first global provider to support customers’ international expansion ambitions with ETSI and the UK Digital Identity and Attributes Trust Framework certification.
  • Certifying for ETSI TS 119 461 distinguishes Onfido’s ability to serve globally and comply locally.
  • “ETSI TS 119 461 for identity verification provides a new standard for security, interoperability and assurance across the industry while setting the foundation for issuing trust services in future, such as qualified electronic signatures (QES).

BioMark Unveils Significant Scientific Advancements from Its Leading Liquid Biopsy Technology at ASCO 2023 Annual Meeting

Retrieved on: 
Monday, June 5, 2023

BioMark's blood-based metabolomic biomarker panel clinically improved early-stage lung cancer detection through stage shifting.

Key Points: 
  • The poster will also be available on our website following the conclusion of the meeting.
  • "The blood-based metabolites panel validated on our current retrospective study yielded sensitivity of 91% and specificity over 78% for all resectable lung cancer detection.
  • "We remain focused and committed in the commercialization of this important molecular assay that addresses a significant need in improving cancer management related in early lung cancer detection.
  • BioMark is poised to take it's blood-based metabolomic biomarker panel to the next level and bring new hope to people at high risk of developing lung cancer."

Source Protocol Partners with Industry-Leading Charitable Giving Platform, GivBux, to Bridge the Gap Between Crypto and Real-World Utility

Retrieved on: 
Wednesday, May 24, 2023

Tortola, British Virgin Island, May 24, 2023 (GLOBE NEWSWIRE) --   Source Protocol recently solidified a long-term partnership with GivBux, a publicly-traded super app, and charitable giving platform. Their shared goal is to enhance GivBux’s mobile wallet feature sets, rewards program, and overall user experience via Source’s advanced Web 3.0 technology suite.

Key Points: 
  • Tortola, British Virgin Island, May 24, 2023 (GLOBE NEWSWIRE) -- Source Protocol recently solidified a long-term partnership with GivBux , a publicly-traded super app , and charitable giving platform.
  • Their shared goal is to enhance GivBux’s mobile wallet feature sets, rewards program, and overall user experience via Source’s advanced Web 3.0 technology suite.
  • They also allow users to send and receive funds and gifts and get rewarded for using the app in general.
  • This will give many cryptocurrencies a level of utility they cannot receive anywhere else, with the added bonus of sponsored charitable donations.

BioMark Announces Update from Ongoing Clinical Trial Using Its Lung Cancer Liquid Biopsy Test as It Prepares for Commercial Launch

Retrieved on: 
Wednesday, January 11, 2023

As clinical trial success relies on effective patient recruitment, BioMark is delighted to announce today that enrollment for its pivotal lung cancer screening study exceeded 1000 participants in less than one year.

Key Points: 
  • As clinical trial success relies on effective patient recruitment, BioMark is delighted to announce today that enrollment for its pivotal lung cancer screening study exceeded 1000 participants in less than one year.
  • The Company also announces its first international patient recruited as part of a European prospective lung cancer screening trial in France known as the ILYAD study.
  • The Company intends to pursue clinical validation of the test as a laboratory developed test (LDT) in parallel with these ongoing studies.
  • The BioMark Lung Cancer Risk Assessment Test will be available through its Quebec-based accredited laboratory, BioMark Diagnostic Solutions Inc., within approximately 9 - 12 months based on the completion of the ISO 15-189 certification.

Unified Payments Platform, NomuPay, Announces Formation of Global Board of Directors

Retrieved on: 
Tuesday, December 6, 2022

DUBLIN, Ireland, Dec. 6, 2022 /PRNewswire/ -NomuPay Group, a fast-growth financial technology company, today announced the formation of its Global Board of Directors .

Key Points: 
  • DUBLIN, Ireland, Dec. 6, 2022 /PRNewswire/ -NomuPay Group, a fast-growth financial technology company, today announced the formation of its Global Board of Directors .
  • "I am extremely excited to welcome these four individuals to the NomuPay Board and team," said Peter Burridge, Group CEO.
  • A modern end-to-end payment platform purpose-built for expansion into regions of high cross-border and ecommerce growth, NomuPay's Unified Payments (uP) Platform provides omnichannel payments acceptance and payout disbursements through a single API integration.
  • Prior to GoFundMe, Juan was General Manager of Braintree, a global payments company that was acquired by PayPal in 2013.

Unified Payments Platform, NomuPay, Announces Formation of Global Board of Directors

Retrieved on: 
Tuesday, December 6, 2022

DUBLIN, Ireland, Dec. 6, 2022 /PRNewswire/ -- NomuPay Group, a fast-growth financial technology company, today announced the formation of its Global Board of Directors .

Key Points: 
  • DUBLIN, Ireland, Dec. 6, 2022 /PRNewswire/ -- NomuPay Group, a fast-growth financial technology company, today announced the formation of its Global Board of Directors .
  • "I am extremely excited to welcome these four individuals to the NomuPay Board and team," said Peter Burridge, Group CEO.
  • A modern end-to-end payment platform purpose-built for expansion into regions of high cross-border and ecommerce growth, NomuPay's Unified Payments (uP) Platform provides omnichannel payments acceptance and payout disbursements through a single API integration.
  • Prior to GoFundMe, Juan was General Manager of Braintree, a global payments company that was acquired by PayPal in 2013.

Prosus N.V.: Press Related to TENCENT

Retrieved on: 
Tuesday, November 1, 2022

Prosus N.V. (Prosus) (AEX and JSE: PRX): Shareholders are referred to article published on 31 October 2022 by Asian Tech Press.

Key Points: 
  • Prosus N.V. (Prosus) (AEX and JSE: PRX): Shareholders are referred to article published on 31 October 2022 by Asian Tech Press.
  • The Group continues with its open-ended share repurchase programme announced in June this year which is funded by the sale of small numbers of ordinary shares in Tencent Holdings Limited (Tencent) held by the Group (Tencent Shares) regularly and in an orderly manner.
  • Prosus is a global consumer internet group and one of the largest technology investors in the world.
  • Operating and investing globally in markets with long-term growth potential, Prosus builds leading consumer internet companies that empower people and enrich communities.

Prosus N.V.: Termination of Agreement to Acquire BillDesk

Retrieved on: 
Monday, October 3, 2022

Prosus N.V. (Prosus) (AEX and JSE: PRX): On 31 August 2021, Prosus announced that an agreement had been reached between PayU Payments Private Limited (PayU), a subsidiary of Prosus, and the shareholders of the Indian digital payments provider BillDesk to acquire BillDesk for US$4.7 billion.

Key Points: 
  • Prosus N.V. (Prosus) (AEX and JSE: PRX): On 31 August 2021, Prosus announced that an agreement had been reached between PayU Payments Private Limited (PayU), a subsidiary of Prosus, and the shareholders of the Indian digital payments provider BillDesk to acquire BillDesk for US$4.7 billion.
  • Prosus has been a long-term investor and operator in India - investing close to US$6 billion in Indian technology companies since 2005.
  • Prosus remains committed to the Indian market and growing its existing businesses within the region.
  • Operating and investing globally in markets with long-term growth potential, Prosus builds leading consumer internet companies that empower people and enrich communities.

Prosus to acquire remaining stake in iFood from Just Eat

Retrieved on: 
Friday, August 19, 2022

Following the transaction, Prosus and its affiliate company, Movile (a Brazilian investor in technology companies) will fully own iFood.

Key Points: 
  • Following the transaction, Prosus and its affiliate company, Movile (a Brazilian investor in technology companies) will fully own iFood.
  • iFood has performed exceptionally well since Prosus first invested in the business through Movile, founded by Fabricio Bloisi, in 2013.
  • Today, iFood is a leading platform business which includes food delivery, grocery, quick commerce, and fintech.
  • We first invested in iFood nearly a decade ago and during this time Fabricio and team have built a world-class food delivery business.

Prosus delivers strong revenue growth with profitable core operations; announces open-ended share repurchase programme

Retrieved on: 
Monday, June 27, 2022

This performance was led by 93% growth in Classifieds, 77% growth in Food Delivery, 55% growth in Edtech and 45% growth in Payments & Fintech.

Key Points: 
  • This performance was led by 93% growth in Classifieds, 77% growth in Food Delivery, 55% growth in Edtech and 45% growth in Payments & Fintech.
  • Classifieds, as well as core payments, remain profitable, with trading profit of profitable ecommerce businesses increasing 17% to US$493m.
  • With strong operational execution, good consumer traction, and improving profitability in core operations, the Group increased investment to pursue opportunities for each segment.
  • A detailed breakdown of the Net Asset Value of the Prosus portfolio, based on market consensus estimates, is on the Prosus website here .